Siemens Healthineers and Novo Join Forces to Advance Care for People Living with MASLD and MASH

Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) --

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The companies are engaged in several projects to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing.